This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jourenkova-Mironova, N. Articles by Hirvonen, A. Search for Related Content PubMed PubMed Citation Articles by Jourenkova-Mironova, N. Articles by Hirvonen, A.

Glutathione S-Transferase GSTM3 and GSTP1 Genotypes and Larynx Cancer Risk¹

Unit of Cancer Epidemiology (Institut National de la Santé et de la Recherche Médicale U351), Institut Gustave-Roussy, 94805 Villejuif, France [N. J-M., S. B.]; Department of Industrial Hygiene and Toxicology, Finnish Institute of Occupational Health, 00250, Helsinki, Finland [A. V., H. W., A. H.]; Geneva Cancer Registry, 1205 Geneva, Switzerland [C. B.]; and Division of Clinical Pharmacology, University Hospital of Geneva, 1211 Geneva, Switzerland [P. D.]

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Glutathione S-transferases (GSTs) are involved in detoxification of reactive metabolites of carcinogens and, therefore, could be potentially important in susceptibility to cancer. The associations between larynx cancer risk and GSTM3 and GSTP1 gene polymorphisms, either separately or in combination with GSTM1 and GSTT1 gene polymorphisms, were evaluated using peripheral blood DNA from 129 cancer patients and 172 controls, all regular smokers. The frequencies of GSTM3 AA, AB, and BB genotypes were 60.5%, 36.4%, and 3.1% in cases and 72.7%, 24.4%, and 2.9% in controls, respectively. The frequencies of GSTP1 AA, AG, and GG genotypes were 48.1%, 40.3%, and 11.6% in cases and 50.0%, 37.2%, and 12.8% in controls, respectively. Multivariate logistic regression analyses did not reveal any association between the GSTP1 (AG or GG) genotype and larynx cancer [odds ratio, 1.1; 95% confidence interval (CI), 0.7–2.0]. In contrast, a significant increase in risk was related to the GSTM3 (AB or BB) genotype (odds ratio, 2.0; 95% CI, 1.1–3.4). The combined GSTM3 (AB or BB) and GSTM1-null genotype conferred a 4-fold risk (95% CI, 1.6–10.1) of larynx cancer as compared with the combined GSTM3 AA and GSTM1-positive genotype. However, the effect of GSTM3 (AB or BB) genotype was similar among individuals with GSTM1-positive or GSTM1-null genotypes.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
GSTs³ are a family of cytosolic enzymes that are potentially important in regulating susceptibility to cancer due to their ability to metabolize reactive metabolites of carcinogens (1) . Among them, GSTM1 and GSTT1 have attracted most of the interest (2) , mainly because they are involved in detoxification of reactive metabolites of carcinogenic substances from tobacco smoke (3) . The absence of GSTM1 and GSTT1 enzyme activities in approximately 50% and 20% of Caucasians, respectively, are due to homozygous inherited deletion in the respective genes (null genotype; Refs. 4 and 5 ). Results from the previous studies on larynx cancer risk associated with the GSTM1 phenotype/genotype or the GSTT1 genotype have been inconclusive, and only a moderate increase in risk, if any, was observed (6, 7, 8, 9) . One of the possible reasons of the divergent findings may rely on polymorphisms of other relevant GST genes (10 , 11) .

Recently, polymorphisms in GSTM3 and GSTP1 loci were reported (12 , 13) . In the GSTM3 gene, the GSTM3*A wild type allele and the GSTM3*B variant allele have been described (12) . The GSTM3*B contains a recognition motif for the YY1 transcription factor that has been postulated to regulate gene expression (14) . It was suggested that GSTM3*A and GSTM3*B are expressed at different levels. Although relatively little is known about the role of GSTM3 in the metabolism of harmful agents, it is known to have overlapping substrate specificities with GSTM1 (15) . The GSTM3 polymorphism could, therefore, confer different efficiencies in the metabolism of carcinogens (16) . In a recent study, an increase in larynx cancer risk associated with GSTM3 AA genotype was suggested (8) .

GSTP1 has been shown to detoxify active metabolites of polycyclic aromatic hydrocarbons, one of the main carcinogens of tobacco smoke (13) . In the GSTP1 gene, two variant alleles, GSTP1*B and GSTP1*C, have been detected in addition to the wild type allele GSTP1*A (13) . Both variant alleles have an A₃₁₃G transition, causing a change of isoleucine to Val. The specific activity and affinity for electrophilic substrates is altered in the Val variant (13) . In a recent study, lack of association between polymorphism at the GSTP1 locus and larynx cancer was observed (17) .

We previously reported that the GSTM1-null genotype conferred an increased risk of larynx cancer; the risk linked to GSTT1-null genotype was also increased, although not significantly (9) . Additional genotyping tests were performed to examine the role of GSTM3 and GSTP1 polymorphisms in larynx cancer susceptibility.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Subjects were recruited in France from 1988–1992, and the study population has been described previously (9) . In brief, cases were Caucasian patients with histologically confirmed primary squamous cell carcinoma of the larynx. A control group, frequency matched on age, sex, and hospital, consisted of all eligible Caucasian patients without previous or present malignant disease. Only regular smokers, defined as people having smoked at least five cigarettes (or cigars or pipes) per day for at least 5 years, were included. Detailed information on lifetime tobacco use and alcohol consumption was recorded during a personal interview. Participation rates were not formally recorded. Discussions with interviewers suggest that almost all eligible cases and controls agreed to participate. Blood samples from 129 larynx cancer patients and 172 controls fulfilling the above-mentioned criteria were collected in EDTA tubes and stored at -20°C. The main diseases diagnosed in the control population were rheumatological (33%), infectious and parasitic (10%), respiratory (9%), cardiovascular (8%), digestive (6%), and traumatological (6%). The main motive for admission to hospital was related to general symptoms (7.0%) for the other categories. The age distributions were quite similar in cases (55.0 years) and controls (54.9 years). Most of the study subjects were men (98% of cases and 95% of controls). Cases had a higher average daily tobacco consumption than controls (30.4 g/day versus 25.1 g/day) and a longer duration of smoking (34.6 years versus 32.2 years). The mean daily consumption of alcohol was higher in larynx cancer cases than in controls (98.1 g/day versus 77.1 g/day).

Genotyping.
Extraction of total WBC DNA was performed using standard protocols. A multiplex PCR method was used to detect the presence or absence of GSTM1 and GSTT1 genes, as described earlier (18 , 19) .

The allelic variants of GSTM3 and GSTP1 genes were differentiated from the wild-type alleles by PCR-RFLP based methods, as described previously (12 , 20) .

Statistical Analysis.
ORs and 95% CIs associated with GST genotypes were calculated by unconditional logistic regression using Statistical Analysis Software, version 6.11 (21) . ORs were adjusted for sex, age, and smoking- and alcohol-related variables, as described previously (9) . As there were no women among glottic/subglottic larynx cancer patients, analyses in this subpopulation were restricted to men.

Gene-gene interactions and gene-smoking interactions were evaluated by the likelihood ratio test to compare the goodness of fit of the model with and without interaction term (22) . To this end, the average daily consumption of tobacco and the duration of smoking were expressed as continuous or as categorical variables (22) , the latter defined with two levels of smoking exposure according to the approximate median in the control population. Due to small numbers, the GSTM3 AB and BB genotypes, as well as the GSTP1 AG and GG genotypes, were combined in most analyses.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
The GSTM3 and GSTP1 genotype distributions in the control population were in agreement with those predicted under the conditions of Hardy-Weinberg equilibrium (P = 0.58 and P = 0.18, respectively). The difference in the distribution of GSTM3 AA, AB, and BB genotypes between larynx cancer cases and controls was nearly significant (P <0.08; Table 1 ); this was explained by the lower frequency of subjects with the GSTM3 AA genotype in cases (60.5%) than in controls (72.7%). In contrast, the distribution of GSTP1 AA, AG, and GG genotypes was similar in both groups (Table 1) . The frequency of the GSTM3 AA genotype was significantly higher in carriers of the GSTM1-null genotype than in those with the GSTM1-positive genotype, both among larynx cancer patients (70.4% versus 45.1%; P <0.01) and among controls (80.0% versus 64.6%; P <0.05).

Similar results were observed when analyses were restricted to men or when supraglottic and glottic/subglottic larynx cancer cases were studied separately (Table 1) .

The ORs of larynx cancer linked to different GST genotype combinations are shown in Table 2 . Compared with the combined GSTM3 AA- and GSTM1-positive genotype, a significant increase in risk associated with the combined GSTM3 (AB or BB) was found both in carriers of GSTM1-positive genotype (OR, 3.2; 95% CI, 1.4–7.3) and in carriers of GSTM1-null genotype (OR, 4.0; 95% CI, 1.6–10.1). Similarly, the effect of GSTM3 (AB or BB) genotype was not modified by the GSTT1 genotype. Larynx cancer risks related to GSTP1 (AG or GG) genotype were similar in carriers of GSTM1 or GSTT1 gene deletion and carriers of positive GSTM1 or GSTT1 genotypes.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Active metabolites of polycyclic aromatic hydrocarbons from tobacco smoke are partly detoxified by GSTP1 enzyme. Polymorphism at the GSTP1 gene could, therefore, be relevant in smoking-related cancers. In agreement with the sole previous study on larynx cancer (17) , we failed to find increased risk linked to the potentially harmful GSTP1 (AG or GG) genotype. Although it was noted that isoleucine to Val substitution in the GSTP1 protein leads to changes in its catalytic properties in vitro (23) , it is possible that these changes do not result in important impairment of tobacco-related carcinogen metabolism by GSTP1 in human larynx.

Although the combined GSTM3 (AB or BB) and GSTM1-null genotype conferred the highest larynx cancer risk, the ORs associated with at-risk GSTM3 or GSTP1 genotypes were similar in carriers of GSTM1- or GSTT1-positive and -null genotypes. The lack of gene-gene interactions could be due to low statistical power because of rather small numbers of individuals or could fit the hypothesis that each of GST enzymes may act independently in carcinogen metabolism.

In summary, the present data suggest that the GSTM3 (AB or BB) genotype confers an increased risk of larynx cancer. In contrast, larynx cancer risk was not associated with GSTP1 gene polymorphism. These findings need confirmation in other investigations and should give impetus to large studies on interactive effects of different GST genotypes.

	Acknowledgments

 
We thank R. Striberni for expert technical help and C. Paoletti, M. Labbé, and C. Massoud for technical assistance. We are also indebted to the consultants and chiefs of Clinical units who allowed us to study their patients for the purpose of the study: Drs. G. Akoun, R. Arriagada, P. Baldeyrou, F. Besançon, A. Bisson, M. Bisson, F. Blanchet, F. Blanchon, A. Bouchiki, J. Brugère, C. Buffet, J. P. Camus, R. Caquet, Y. Chapuis, D. Chassagne, P. Constans, B. Dautzenberg, J. Debray, J. P. Derenne, P. Duroux, J. Fain, G. Freyss, A. Gerbaulet, Ph. Girard, J. Guerre, P. Guibout, H. Hamard, B. Housset, J. C. Imbert, F. Janot, A. Jardin, T. Le Chevalier, B. Lebeau, A. M. Leridant, Ph. Levasseur, V. G. Levy, A. Livartowski, G. Loyau, B. Luboinski, G. Mamelle, F. Mazas, P. Marandas, C. Menkes, H. Mondon, J. P. Passeron, J. Piquet, A. Rivière, M. Robillard, J. Rochemaure, R. Roy-Camille, J. C. Saltiel, G. Schwaab, J. M. Segrestaa, D. Sereni, M. Spielmann, P. Testas, G. Tobelem, and P. Vige.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by the Swiss Cancer League, Switzerland (FOR063), League against Cancer of Fribourg, Switzerland (FOR381.88), Cancer Research, Switzerland (AKT 617), and Fund for Clinical Research against Cancer, Gustave-Roussy Institute, Villejuif, France (88D28). N. J-M. held a fellowship from La Ligue Nationale contre le Cancer (Paris, France).

² To whom requests for reprints should be addressed, at INSERM 351, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif cedex, France. Phone: 33-1-42-11-41-39; Fax: 33-1-42-11-53-15; E-mail: simone.benhamou{at}igr.fr

³ The abbreviations used are: GST, glutathione S-transferase; Val, valine; OR, odds ratio; CI, confidence interval.

Received 3/31/98; revised 10/26/98; accepted 11/ 9/98.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Seidegard J., Ekstrom G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ. Health Perspect., 105 (Suppl. 4): 791-799, 1997.
2. Rebbeck T. R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomark. Prev., 6: 733-743, 1997.[Abstract]
3. Ketterer B., Harris J. M., Talaska G., Meyer D. J., Pemble S. E., Taylor J. B., Lang N. P., Kadlubar F. F. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ. Health Perspect., 98: 87-94, 1992.[Medline]
4. Seidegard J., Vorachek W. R., Pero R. W. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. USA, 85: 7293-7297, 1988.[Abstract/Free Full Text]
5. Pemble S., Schroeder K. R., Spencer S. R., Meyer D. J., Hallier E., Bolt H. M., Ketterer B., Taylor J. B. Human glutathione S-transferase (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J., 300: 271-276, 1994.
6. Lafuente A., Pujol F., Carretero P., Villa J. P., Cuchi A. Human glutathione S-transferase µ (GST µ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett., 68: 49-54, 1993.[Medline]
7. Coutelle C., Ward P. J., Fleury B., Quattrocchi P., Chambrin H., Iron A., Couzigou P., Cassaigne A. Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum. Genet., 99: 319-325, 1997.[Medline]
8. Matthias C., Bockmühl U., Jahnke V., Jones P. W., Hayes J. D., Alldersea J., Gilford J., Bailey L., Bath J., Worrall S. F., Hand P., Fryer A. A., Strange R. C. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics, 8: 91-100, 1998.[Medline]
9. Jourenkova N., Reinikainen M., Bouchardy C., Dayer P., Benhamou S., Hirvonen A. Larynx cancer risk in relation to glutathione S-transferases M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol. Biomark. Prev., 7: 19-24, 1998.[Abstract]
10. Strange R. Glutathione S-transferases and cancer susceptibility Vermeulen N. P. E. Mulder G. J. Nieuwenhuyse H. Peters W. H. M. Van Bladeren P. J. eds. . Glutathione S-Transferases: Structure, Function and Clinical Implications, : 239-248, Taylor and Francis London 1996.
11. Hirvonen A. Combinations of susceptible genotypes and individual responses to toxicants. Environ. Health Perspect., 105 (Suppl 4): 755-758, 1997.
12. Inskip A., Elexperu-Camiruaga J., Buxton N., Dias P. S., MacIntosh J., Campbell D., Jones P. W., Yengi L., Talbot J. A., Strange R. C., Fryer A. A. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochem. J., 312: 713-716, 1995.
13. Ali-Osman F., Akande O., Antoun G., Mao J. X., Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem., 272: 10004-10012, 1997.[Abstract/Free Full Text]
14. Becker K. G., Jedlicka P., Templeton N. S., Liotta L., Ozato K. Characterization of hUCRBP (YY1, NF-E1, ): a transcription factor that binds the regulatory regions of many viral and cellular genes. Gene, 150: 259-266, 1994.[Medline]
15. Hayes J. D., Pulford D. J. The glutathione S-transferase supergene family: regulation of GST and contribution of isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol., 30: 445-600, 1995.[Medline]
16. Yengi L., Inskip A., Gilford J., Alldersea J., Bailey L., Smith A., Lear J. T., Heagerty A. H., Bowers B., Hand P., Hayes J. D., Jones P. W., Strange R. C., Fryer A. A. Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res., 56: 1974-1977, 1996.[Abstract/Free Full Text]
17. Matthias C., Bockmühl U., Jahnke V., Harries L. W., Wolf C. R., Jones P. W., Alldersea J., Worrall S. F., Hand P., Fryer A. A., Strange R. C. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics, 8: 1-6, 1998.[Medline]
18. Hirvonen A., Saarikoski S. T., Linnainmaa K., Koskinen K., Husgafvel-Pursiainen K., Mattson K., Vainio H. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J. Natl. Cancer Inst., 88: 1853-1856, 1996.[Abstract/Free Full Text]
19. Chen H., Sandler D. P., Taylor J. A., Shore D. L., Liu E., Bloomfield C. D., Bell D. A. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase 1 (GSTT1) gene defect. Lancet, 347: 295-297, 1996.[Medline]
20. Saarkoski, S., Voho, A., Reinikainen, M., Anttila, S., Karjalainen, A., Malaveille, C., Vainio, H., Husgafvel-Pursiainen, K., Hirvonen, A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int. J. Cancer, in press, 1998.
21. SAS Institute Inc. Logistic Regression Examples Using the SAS System, Version 6, Ed. 1. Cary, NC: SAS Institute Inc., 1995.
22. Breslow N. E., Day N. E. Statistical Methods in Cancer Research. I. The Analysis of Case-Control Studies. IARC Sci. Publ., 32: 192-242, 1980.
23. Zimniak P., Nanduri B., Pikula S., Bandorowicz-Pikula J., Singhal S. S., Srivastava S. K., Awasthi S., Awasthi Y. C. Naturally occurring human glutathione S-transferase GSTP1–1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem., 224: 893-899, 1994.[Medline]

This article has been cited by other articles:

				M. Jain, S. Kumar, P. Lal, A. Tiwari, U. C. Ghoshal, and B. Mittal Role of GSTM3 Polymorphism in the Risk of Developing Esophageal Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 178 - 181. [Abstract] [Full Text] [PDF]

				Z Ye, H Song, and Y Guo Glutathione S-transferase M1, T1 status and the risk of head and neck cancer: a meta-analysis J. Med. Genet., May 1, 2004; 41(5): 360 - 365. [Full Text] [PDF]

				M. Hashibe, P. Brennan, R. C. Strange, R. Bhisey, I. Cascorbi, P. Lazarus, M. B. O. Ophuis, S. Benhamou, W. D. Foulkes, T. Katoh, et al. Meta- and Pooled Analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 Genotypes and Risk of Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1509 - 1517. [Abstract] [Full Text] [PDF]

				S. Garte Metabolic Susceptibility Genes As Cancer Risk Factors: Time for a Reassessment? Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1233 - 1237. [Abstract] [Full Text] [PDF]

				A. Loktionov, M. A. Watson, M. Gunter, W. S.L. Stebbings, C. T.M. Speakman, and S. A. Bingham Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor Carcinogenesis, July 1, 2001; 22(7): 1053 - 1060. [Abstract] [Full Text] [PDF]

				A. F. Olshan, M. C. Weissler, M. A. Watson, and D. A. Bell GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 Polymorphisms, Tobacco Use, and the Risk of Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 185 - 191. [Abstract] [Full Text]

				R. M. Whyatt, F. P. Perera, W. Jedrychowski, R. M. Santella, S. Garte, and D. A. Bell Association between Polycyclic Aromatic Hydrocarbon-DNA Adduct Levels in Maternal and Newborn White Blood Cells and Glutathione S-Transferase P1 and CYP1A1 Polymorphisms Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 207 - 212. [Abstract] [Full Text]

				C. Matthias, V. Jahnke, P. W. Jones, P. R. Hoban, J. E. Alldersea, S. F. Worrall, A. A. Fryer, and R. C. Strange Cyclin D1, Glutathione S-Transferase, and Cytochrome P450 Genotypes and Outcome in Patients with Upper Aerodigestive Tract Cancers: Assessment of the Importance of Individual Genes Using Multivariate Analysis Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 815 - 823. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jourenkova-Mironova, N. Articles by Hirvonen, A. Search for Related Content PubMed PubMed Citation Articles by Jourenkova-Mironova, N. Articles by Hirvonen, A.